Buspirone hydrochloride
Buspirone hydrochloride structure
|
Common Name | Buspirone hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 33386-08-2 | Molecular Weight | 421.96400 | |
| Density | 1.24g/cm3 | Boiling Point | 613.9ºC at 760mmHg | |
| Molecular Formula | C21H32ClN5O2 | Melting Point | 201.5-202.50C | |
| MSDS | Chinese USA | Flash Point | 325.1ºC | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.
Eur. J. Drug Metab. Pharmacokinet. 38(4) , 223-9, (2013) The area of fruit juice-drug interaction has received wide attention with numerous scientific and clinical investigations performed and reported for scores of drugs metabolized by CYP3A4/CYP2C9. While grapefruit juice has been extensively studied with respect... |
|
|
Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine.
Arch. Gynecol. Obstet. 287(3) , 469-72, (2013) The premenstrual syndrome (PMS), which causes emotional and physical symptoms, is a common problem in many women in their reproductive age. Many approaches to PMS with controversial results are available. The present study was performed to compare fluoxetine ... |
|
|
Two weeks of buspirone protects against posthypoxic ventilatory pauses in the C57BL/6J mouse strain
Respir. Physiol. Neurobiol. 183(1) , 35-40, (2012) The purpose was to determine if 2 weeks of buspirone suppressed post-hypoxic breathing instability and pauses in the C57BL/6J (B6) mouse. Study groups were vehicle (saline, n=8), low-dose (1.5mg/kg, n=8), and high-dose buspirone (5.0mg/kg, n=8). Frequency, me... |
|
|
Development of oral extended release formulations of 6-hydroxybuspirone.
Biopharm. Drug Dispos. 33(9) , 522-35, (2012) Reducing the maximum plasma concentration whilst maintaining the exposure was shown to ameliorate adverse events following the oral administration of 6-hydroxybuspirone. This observation, along with a desire to provide for once daily dosing of this compound, ... |
|
|
Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry.
Biomed. Chromatogr. 27(2) , 233-9, (2013) This study firstly describes the development of an accurate and sensitive high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for the quantification of Taiwanin E methyl ether (TEME) in rat plasma. The assay involved a simple liqu... |
|
|
Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats.
Neurosci. Lett. 556 , 210-5, (2013) Serotonin (5-HT)-related drugs are extensively employed in the treatment of mental disorders. However, the roles of the central serotonergic system in impulse control over environmental stimuli remain to be elucidated. The present study demonstrated acute and... |
|
|
Repurposing buspirone for drug addiction treatment.
Int. J. Neuropsychopharmacol. 16(2) , 251-3, (2013)
|
|
|
Performance in anxiety and spatial memory tests following bilateral vestibular loss in the rat and effects of anxiolytic and anxiogenic drugs.
Behav. Brain Res. 235(1) , 21-9, (2012) Vestibular dysfunction in humans is associated with anxiety and cognitive disorders. However, various animal studies of the effects of vestibular loss have yielded conflicting results, from reduced anxiety to increased anxiety, depending on the particular mod... |
|
|
The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone.
Food Chem. Toxicol. 51 , 396-403, (2013) Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum... |
|
|
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
Cerebellum 12(1) , 74-82, (2013) Spinocerebellar ataxias are autosomal dominant diseases, associated in some types with a CAG repeat expansion, and characterised by a progressive loss of motor function. Currently, as there is no cure for most ataxias, treatment predominantly involves physica... |